Literature DB >> 21355075

Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells.

Haiyen E Zhau1, Hui He, Christopher Y Wang, Majd Zayzafoon, Colm Morrissey, Robert L Vessella, Fray F Marshall, Leland W K Chung, Ruoxiang Wang.   

Abstract

PURPOSE: Prostate tumor cells frequently show the features of osteoblasts, which are differentiated from bone marrow mesenchymal stem cells. We examined human prostate cancer cell lines and clinical prostate cancer specimens for additional bone marrow mesenchymal stem cell properties. EXPERIMENTAL
DESIGN: Prostate cancer cell lines were induced for osteoblastogenic and adipogenic differentiation, detected by standard staining methods and confirmed by lineage-specific marker expression. Abnormal expression of the markers was then assessed in clinical prostate cancer specimens.
RESULTS: After osteoblastogenic induction, cells of the LNCaP lineage, PC-3 lineage, and DU145 displayed osteoblastic features. Upon adipogenic induction, PC-3 lineage and DU145 cells differentiated into adipocyte-like cells. The adipocyte-like cancer cells expressed brown adipocyte-specific markers, suggesting differentiation along the brown adipocyte lineage. The adipogenic differentiation was accompanied by growth inhibition, and most of the adipocyte-like cancer cells were committed to apoptotic death. During cyclic treatments with adipogenic differentiation medium and then with control medium, the cancer cells could commit to repeated adipogenic differentiation and retrodifferentiation. In clinical prostate cancer specimens, the expression of uncoupling protein 1 (UCP1), a brown fat-specific marker, was enhanced with the level of expression correlated to disease progression from primary to bone metastatic cancers.
CONCLUSIONS: This study thus revealed that prostate cancer cells harbor the stem cell properties of bone marrow mesenchymal stem cells. The abnormally expressed adipogenic UCP1 protein may serve as a unique marker, while adipogenic induction can be explored as a differentiation therapy for prostate cancer progression and bone metastasis. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21355075      PMCID: PMC3085118          DOI: 10.1158/1078-0432.CCR-10-2523

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells.

Authors:  Ulrich Nöth; Anna M Osyczka; Richard Tuli; Noreen J Hickok; Keith G Danielson; Rocky S Tuan
Journal:  J Orthop Res       Date:  2002-09       Impact factor: 3.494

2.  Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

Authors:  D L Lin; C P Tarnowski; J Zhang; J Dai; E Rohn; A H Patel; M D Morris; E T Keller
Journal:  Prostate       Date:  2001-05-15       Impact factor: 4.104

Review 3.  Rejuvenation in distinct cell populations - What does it mean?

Authors:  Ralf Hass
Journal:  Exp Gerontol       Date:  2009-07-26       Impact factor: 4.032

Review 4.  The mitochondrial uncoupling protein UCP1: a gated pore.

Authors:  I Arechaga; A Ledesma; E Rial
Journal:  IUBMB Life       Date:  2001 Sep-Nov       Impact factor: 3.885

5.  Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia.

Authors:  C Bing; M Brown; P King; P Collins; M J Tisdale; G Williams
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

Review 6.  Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.

Authors:  E Fosslien
Journal:  Crit Rev Clin Lab Sci       Date:  2000-10       Impact factor: 6.250

7.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Authors:  Martine P Roudier; Lawrence D True; Celestia S Higano; Hubert Vesselle; William Ellis; Paul Lange; Robert L Vessella
Journal:  Hum Pathol       Date:  2003-07       Impact factor: 3.466

8.  Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function.

Authors:  Kristen D Brubaker; Robert L Vessella; Lisha G Brown; Eva Corey
Journal:  Prostate       Date:  2003-06-15       Impact factor: 4.104

Review 9.  The role of uncoupling proteins in pathophysiological states.

Authors:  Josep M Argilés; Sílvia Busquets; Francisco J López-Soriano
Journal:  Biochem Biophys Res Commun       Date:  2002-05-17       Impact factor: 3.575

10.  Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.

Authors:  Hiroyuki Kubo; Thomas A Gardner; Yoshitaka Wada; Kenneth S Koeneman; Akinobu Gotoh; Ling Yang; Chinghai Kao; So Dug Lim; Mahul B Amin; Hua Yang; Margaret E Black; Shigeji Matsubara; Masayuki Nakagawa; Jay Y Gillenwater; Haiyen E Zhau; Leland W K Chung
Journal:  Hum Gene Ther       Date:  2003-02-10       Impact factor: 5.695

View more
  26 in total

1.  CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.

Authors:  H J Wright; J Arulmoli; M Motazedi; L J Nelson; F S Heinemann; L A Flanagan; O V Razorenova
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

2.  Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production.

Authors:  Karen McLean; Yusong Gong; Yunjung Choi; Ning Deng; Kun Yang; Shoumei Bai; Lourdes Cabrera; Evan Keller; Laurie McCauley; Kathleen R Cho; Ronald J Buckanovich
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

3.  Pyranocoumarin Tissue Distribution, Plasma Metabolome and Prostate Transcriptome Impacts of Sub-Chronic Exposure to Korean Angelica Supplement in Mice.

Authors:  Jinhui Zhang; Li Li; Suni Tang; Yong Zhang; Maciej Markiewski; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  Am J Chin Med       Date:  2016       Impact factor: 4.667

Review 4.  The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Authors:  Rhonda L Bitting; Daneen Schaeffer; Jason A Somarelli; Mariano A Garcia-Blanco; Andrew J Armstrong
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 5.  Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors.

Authors:  Yusuke Shiozawa; Matthew R Eber; Janice E Berry; Russell S Taichman
Journal:  Bonekey Rep       Date:  2015-05-20

Review 6.  Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

Authors:  Andrew J Armstrong; Mario A Eisenberger; Susan Halabi; Stephane Oudard; David M Nanus; Daniel P Petrylak; A Oliver Sartor; Howard I Scher
Journal:  Eur Urol       Date:  2011-11-12       Impact factor: 20.096

7.  A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases.

Authors:  Konghe Hu; Xinyue Hu; Yang Duan; Wenqiang Li; Jing Qian; Junjie Chen
Journal:  Front Med (Lausanne)       Date:  2022-06-16

8.  TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.

Authors:  Dayson Moreira; Qifang Zhang; Dewan Md S Hossain; Sergey Nechaev; Haiqing Li; Claudia M Kowolik; Massimo D'Apuzzo; Stephen Forman; Jeremy Jones; Sumanta K Pal; Marcin Kortylewski
Journal:  Oncotarget       Date:  2015-07-10

9.  Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.

Authors:  Anna Laurenzana; Manjola Balliu; Cristina Cellai; Maria Novella Romanelli; Francesco Paoletti
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

10.  Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer.

Authors:  Shian-Ying Sung; Chia-Hui Liao; Hsun-Pai Wu; Wan-Chi Hsiao; I-Hui Wu; Sue-Hwa Lin; Chia-Ling Hsieh
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.